Stocks Health care MEDP
NASDAQ · Health careMedpace Holdings, Inc. (MEDP)
Medpace Holdings, Inc. brought in $2.8B of revenue over the twelve months to September 30, 2026, up 20.4% from a year earlier. Net income was $517.8M, a net margin of 18.2%. Operating cash flow minus capital spending left $681.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $705.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 22, 2026.
Key facts about Medpace Holdings, Inc.
- Net worth
- Medpace Holdings, Inc. has a market value (market cap) of $18.8B at the latest share price, and shareholders' equity of $584.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $2.5B (+20.0% year on year), with net income of $451.1M. Over the 12 months to September 30, 2026: revenue $2.8B, net income $517.8M.
- Cash flow
- In fiscal 2025 operations brought in $713.2M of cash; after $31.4M of capital spending, free cash flow was $681.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 22, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Medpace Holdings, Inc.'s next report is expected around February 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Medpace Holdings, Inc. does
Medpace Holdings, Inc. is registered with the SEC under industry code SIC 8731 (Services-Commercial Physical & Biological Research). Its shares trade on NASDAQ under the ticker MEDP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $2.5B | $451.1M | $15.28 | $681.9M |
| 2024 | $2.1B | $404.4M | $12.63 | $572.3M |
| 2023 | $1.9B | $282.8M | $8.88 | $396.7M |
| 2022 | $1.5B | $245.4M | $7.28 | $351.2M |
| 2021 | $1.1B | $181.8M | $4.81 | $235.1M |
| 2020 | $925.9M | $145.4M | $3.84 | $227.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MEDP ranks in Health care
Latest SEC filings
What Medpace Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 22, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 8.5% to $716M versus the same quarter last year; diluted EPS $4.84 versus $3.86.
- October 21, 2026
- September 28, 2026Activist stake changed SCHEDULE 13D/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- July 23, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 17% to $707.3M versus the same quarter last year; diluted EPS $4.25 versus $3.10.
- July 22, 2026
- June 4, 2026
- May 19, 2026
- April 23, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 27% to $706.6M versus the same quarter last year; diluted EPS $4.28 versus $3.67.
- April 22, 2026
What is MEDP worth? A DCF from its reported cash flow
Insider trades
What the people running Medpace Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $192M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 29, 2026 | Ewald Stephen PGeneral Counsel & Corp. Secy. | Sold | 1,245 | $859.1K |
| October 27, 2026 | Burwig Susan EExec. VP, Operations | Sold | 3,940 | $2.7M |
| October 26, 2026 | Burwig Susan EExec. VP, Operations | Sold | 16,060 | $10.9M |
| October 26, 2026 | Burwig Susan EExec. VP, Operations | Exercised options | 328 | $54.7K |
| October 21, 2026 | Burwig Susan EExec. VP, Operations | Exercised options | 2,700 | $450.2K |
| October 12, 2026 | Burwig Susan EExec. VP, Operations | Exercised options | 3,000 | $500.2K |
| October 7, 2026 | Burwig Susan EExec. VP, Operations | Exercised options | 2,000 | $333.5K |
| September 30, 2026 | Kraft Robert O.Director | Exercised options | 32 | - |
Who owns MEDP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| August J. Troendle13D, may seek influence with 1 related filers | 19.1% | September 28, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 7.2% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 696 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 2,498,248 | +27,808 |
| Aqr Capital Management LLC | 1,278,935 | -74,902 |
| Vanguard Portfolio Management LLC | 1,133,357 | +11,668 |
| Vanguard Capital Management LLC | 1,026,820 | +15,749 |
| State Street Corp | 710,895 | +28,666 |
| Geode Capital Management, LLC | 710,465 | -34,641 |
| Wasatch Advisors LP | 636,595 | -137,336 |
| Invesco Ltd. | 579,241 | +1,667 |
| Baillie Gifford & Co | 473,211 | -29,980 |
| Arrowstreet Capital, Limited Partnership | 429,012 | +33,243 |
| Renaissance Technologies LLC | 415,588 | -89,080 |
| Dimensional Fund Advisors LP | 397,500 | +49,015 |
| Morgan Stanley | 317,548 | +29,126 |
| UBS Group AG | 303,926 | -36,507 |
| Mawer Investment Management Ltd. | 267,175 | -178,929 |
| Epoch Investment Partners, Inc. | 266,547 | +125,588 |
| TD Asset Management Inc | 263,872 | +130,819 |
| Giverny Capital Inc. | 253,931 | -2,150 |
| Goldman Sachs Group Inc | 250,781 | +82,294 |
| Madison Asset Management, LLC | 243,502 | -18,791 |
Insiders
9 insiders reported holding 484,114 shares in total, about $325.8M at the last price.
| Holder | Shares |
|---|---|
| Troendle August J.President & CEO, Director, 10% owner | 338,225 |
| Burwig Susan EExec. VP, Operations | 54,012 |
| Carley Brian TDirector | 27,861 |
| Ewald Stephen PGeneral Counsel & Corp. Secy. | 19,098 |
| Geiger Jesse JPresident | 15,000 |
| Brady Kevin M.CFO & Treasurer | 12,830 |
| McCarthy Cornelius P. IIIDirector | 12,303 |
| Davenport Fred B JrDirector | 3,798 |
| Kraft Robert O.Director | 987 |
Questions about MEDP
What does Medpace Holdings, Inc. do?
Medpace Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as MEDP. Its shares trade on NASDAQ under the ticker MEDP.
What is Medpace Holdings, Inc.'s net worth?
Medpace Holdings, Inc. has a market value (market cap) of $18.8B at the latest share price, and shareholders' equity of $584.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Medpace Holdings, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $517.8M on revenue of $2.8B, a net margin of 18.2%.
How much revenue does Medpace Holdings, Inc. make?
Over the twelve months to September 30, 2026 Medpace Holdings, Inc. reported revenue of $2.8B. That is 20.4% more than a year earlier.
When did Medpace Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 22, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 2, 2026.
When is Medpace Holdings, Inc.'s next earnings report?
Medpace Holdings, Inc.'s next report is expected around February 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MEDP with
Follow MEDP
Get an email when Medpace Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Medpace Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.